BEAM News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

BE

Mkt Cap

$2.43B

Volume

1.35M

Next Earnings

November 3rd

Loading chart

BE

BEAMBeam Therapeutics Inc. Common Stock

BEAM

Pay with—

Available Balance0.00

BE

Mkt Cap

$2.55B

Volume

1.35M

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtCathie Wood's Ark Invest added to positions in Meta Platforms, Airbnb, and Beam Therapeutics on Monday. Meta surged 11% on momentum from its new Muse AI app and an upgraded price target from Wells Fargo. Airbnb continues strong revenue growth despite headwinds from rising travel costs and regulatory scrutiny. Beam Therapeutics is recovering after recent clinical trial data showed efficacy in its gene-editing treatment for alpha-1 antitrypsin deficiency.The Motley Fool · Sep 22, 2026

Beam Therapeutics to Participate in Upcoming September 2026 Investor ConferencesBeam Therapeutics announced management participation in three major investor conferences in September 2026. The company also reported progress on its BEAM-302 trial in Alpha-1 Antitrypsin Deficiency, with dosing completed for adult and adolescent patients and updated data selected for presentation at the European Respiratory Society Congress 2026.GlobeNewswire Inc. · Aug 31, 2026

As Sickle Cell Innovation Accelerates, Hematologists Signal Demand for a Broader Treatment Arsenal Beyond Gene TherapyHematologists increasingly favor a diverse sickle cell disease treatment landscape combining gene therapies with oral disease-modifying agents. Mitapivat (Agios) surged to the most desired pipeline therapy at 24% physician preference, while BEAM-101 (Beam Therapeutics) and etavopivat (Novo Nordisk) also gained traction. Despite innovation, 70% of hematologists rate unmet need as high, with 51% of SCD patients not optimally managed with current treatments.GlobeNewswire Inc. · Aug 25, 2026

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?Cathie Wood's Ark Invest has significantly increased its position in Beam Therapeutics, a biotech company using base editing technology for genetic treatments. With multiple clinical programs advancing toward FDA approval and sufficient cash runway through mid-2029, Beam could transform into a commercial biotech company. However, the investment remains speculative and dependent on successful clinical trials and regulatory approvals.The Motley Fool · Jul 20, 2026

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth ForecastThe global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety concerns remain significant challenges.GlobeNewswire Inc. · Jul 3, 2026

Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive GrowthThe CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.GlobeNewswire Inc. · Jul 3, 2026

Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has an approved product (Casgevy) and a deeper pipeline, versus Beam Therapeutics, a clinical-stage company with a potentially safer base-editing platform. CRISPR Therapeutics is recommended as the better investment due to its approved product, stronger cash position ($2.4B vs $1.2B), and deeper pipeline, making it less risky despite both stocks carrying clinical trial risks.The Motley Fool · May 26, 2026

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International ConferenceBeam Therapeutics presented additional clinical data from its Phase 1/2 BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD) at the American Thoracic Society conference. The data from 29 patients showed durable efficacy, improved safety profile, and reduction in neutrophil elastase activity. The company plans to pursue an accelerated FDA approval pathway and expects to initiate a pivotal cohort with approximately 50 additional patients in the second half of 2026.GlobeNewswire Inc. · May 18, 2026

S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth DataU.S. equity markets held near record highs despite geopolitical tensions in the Middle East driving oil prices above $100/barrel. The collapse of U.S.-Iran negotiations triggered an energy shock, while major tech developments included OpenAI's partnership with Qualcomm on smartphone processors, Microsoft's loss of exclusive OpenAI access, and China's forced unwinding of Meta's AI acquisition. Consumer weakness emerged with Domino's cutting guidance, while positive credit metrics in auto lending and a gene-editing breakthrough in CRISPR therapy provided bright spots.Investing.com · Apr 27, 2026

3 Biotech Stocks That Could Benefit from the Patent CliffWith a $300 billion patent cliff expected by 2030, biotech M&A activity is surging. The article identifies three gene-editing companies positioned as potential acquisition targets: CRISPR Therapeutics (established with commercial product), Intellia Therapeutics (pioneering in vivo CRISPR editing), and Beam Therapeutics (developing base editing technology). Each offers different risk/reward profiles for investors seeking exposure to one-time cure therapies.Investing.com · Apr 27, 2026

to start trading

BE

BEAMBeam Therapeutics Inc. Common Stock

BEAM

Pay with—

Available Balance0.00

Your PositionYou don't own any BEAM yet.

Related Tickers

Earnings